RAD204

DEVELOPMENT STEP phase-1
SPONSOR MATRIX Radiopharm Theranostics [RADX]
MECHANISM TARGET PD-L1

[THERAPEUTIC_PROFILE]

Target Indications

PD-L1 Positive Solid Tumors

Mechanism Abstract

A nanobody bearing Lu177 isotope

[CLINICAL_TRIALS_REGISTRY]

TOTAL EXTRACTED1
RECRUITING STATUS1
COMPLETED RUNS0
REGISTRY & PHASE
TESTED CONDITION
STUDY TITLE & LIFECYCLE TIMELINES
STATUS
➔
E-P-1NCT06305962
PDL1 Gene MutationNon Small Cell Lung Cancer+7 more
N=30Est. Finish: 2027-12
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
recruiting